EVALUATION OF ANTI-ALZHEIMER ACTIVITY OF ETHANOLIC AND METHANOLIC EXTRACTS OF POLYGONUM GLABRUM AGAINST ALUMINUM CHLORIDE-INDUCED ALZHEIMER’S IN EXPERIMENTAL RATS

  • SUNEESHA Y Department of Pharmacology, Nirmala College of Pharmacy, Atmakur, Andhra Pradesh, India.
  • VINAY KUMAR T Department of Pharmacology, Nirmala College of Pharmacy, Atmakur, Andhra Pradesh, India.

Abstract

Objective: The current study aimed at the investigation of the effectiveness of ethanolic and methanolic extract of Polygonum glabrum in aluminum chloride-induced Alzheimer’s disease in experimental rats.


Methods: The behavioral parameters evaluated by following methods such as Morris water maze test, radial arm maze test, and active avoidance test. Biochemical parameters were also estimated such as acetylcholine and acetylcholine esterase.


Results: Polygonum glabrum extract was instituted to be neuroprotective against AlCl3-induced toxicity. Enhanced learning and memory were allied to the ingestion of extract in rats. Al overload, acetylcholinesterase enzyme hyperactivity is responsible for Alzheimer’s disease which is neutralized or reduced with treatment of extract, which might be due to the synergistic action of its active constituents. Ethanolic extract was shown slightly higher efficacy as compared to methanolic extract.


Conclusion: Based on these current findings, it is suggested that lowering Aβ is an unproven strategy, and it may be time to refocus on other targets for the treatment of this disease, including pathological forms of tau.

Keywords: Alzheimer's disease, beta-amyloid plaque, ABeta peptide

References

1. Kaur K, Kaur R, Kaur M. Recent advances in Alzheimer’s disease: Causes and treatment. Int J Pharm Pharm Sci 2016;8:8-15.
2. Torgal SS, Sugato CH. Effect of metformin and simvastatin in diazepam-and sodium nitrite-induced anterograde amnesia in male Swiss albino mice. Int J Pharm Pharm Sci 2018;10:18-22.
3. Fisiopatología del la Enfermedad de Alzheimer: Nuevos Mecanismos; 2014. Available from: http://www.revneurol.com/sec/RSS/noticias. php?idNoticia=4446.
4. Nichols E, Szoeke CE, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:88-106.
5. Burns A, Jacoby R, Levy R. Neurological signs in Alzheimer’s disease. Age Ageing 1991;20:45-5.
6. Tripathi KD. Essentials of Medical Pharmacology. 6th ed. New Delhi: Jaypee Brothers Medical Publishers Private Ltd.; 2009.
7. Reitz C. Alzheimer’s disease and the amyloid cascade hypothesis: A critical review. Int J Alzheimers Dis 2012;2012:369808.
8. Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. J Comp Neurol 2013;521:4124-44.
9. Sassin I, Schultz C, Thal DR, Rüb U, Arai K, Braak E, et al. Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 2000;100:259-69.
10. Francis PT, Ramírez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer’s disease. Neuropharmacology 2010;59:221-9.
11. Goto Y, Niidome T, Hongo H, Akaike A, Kihara T, Sugimoto H. Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Eur J Pharmacol 2008;583:84-91.
12. Nordberg A, Winblad B. Reduced number of [3H]nicotine and [3H] acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986;72:115-20.
13. Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: Comparison between Alzheimer’s disease and the normal. J Neurochem 1986;47:1948-54.
14. Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, et al. A rare coding variant in TREM2 increases risk for Alzheimer’s disease in Han Chinese. Neurobiol Aging 2016;42:217.
15. Sassin I, Schultz C, Thal DR, Rüb U, Arai K, Braak E, et al. Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 2000;100:259-69.
16. Francis PT, Ramírez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer’s disease. Neuropharmacology 2010;59:221-9.
17. Goto Y, Niidome T, Hongo H, Akaike A, Kihara T, Sugimoto H.Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Eur J Pharmacol 2008;583:84-91.
18. Kilgard MP, Merzenich MM. Cortical map reorganization enabled by nucleus basalis activity. Science 1998;279:1714-8.
19. Van Beek AH, Claassen JA. The cerebrovascular role of the cholinergic neural system in Alzheimer’s disease. Behav Brain Res 2011;221:537-42.
20. Barbelivien A, MacKenzie ET, Dauphin F. Galanin inhibits the vasodilatatory basalocortical cholinergic system in the anaesthetized rat. Neuroreport 1995;6:1849-52.
Statistics
58 Views | 39 Downloads
Citations
How to Cite
Y, S., and V. KUMAR T. “EVALUATION OF ANTI-ALZHEIMER ACTIVITY OF ETHANOLIC AND METHANOLIC EXTRACTS OF POLYGONUM GLABRUM AGAINST ALUMINUM CHLORIDE-INDUCED ALZHEIMER’S IN EXPERIMENTAL RATS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 1, Jan. 2021, pp. 118-25, doi:10.22159/ajpcr.2021.v14i1.39934.
Section
Original Article(s)